TOP HEADLINES

Featured Story

  • Big Pharma consortium rolls out clinical trial investigator platform

    Big Pharma consortium TransCelerate BioPharma has released a portal through which research sites can interact with multiple clinical trial sponsors. The portal is intended to free clinical trial sites from the duplicated workload and administrative burdens associated with using a different portal for each of the sponsors with which they work.

U.K. looks to house software developers at planned cancer research hub

The team behind a planned 10,000-person, 265,000-square-meter cancer research and care hub in London is looking for software developers to occupy some of the site. By housing software companies, biotechs, med-tech developers and other companies in part of the U.K.'s cancer research and care network, the team is aiming to better connect the public and private sectors.

Buzz: Roche weighing up bid for Pacific Biosciences

Roche is reportedly considering continuing its sequencing dealmaking activity with a bid for Pacific Biosciences.

In silico discovery platform drives forward Bavarian Nordic's MRSA vaccine program

Bavarian Nordic has signed up to work with Evaxion Biotech on the development of a vaccine against methicillin-resistant Staphylococcus aureus (MRSA). The project is underpinned by Eden Technology, an in silico vaccine discovery platform that combines data, algorithms and deep learning to unearth antigens.

454 Life Sciences, Ion Torrent founder raises $40M for tech-enabled drug development shop

Jonathan Rothberg, the Yale University entrepreneur who set up 454 Life Sciences and Ion Torrent, has raised $40 million to bankroll his next venture, a tech-enabled drug discovery shop. The startup, LAM Therapeutics, is aiming to leverage advances in genome editing, sequencing, computer science and artificial intelligence to make drug discovery cheaper and more precise.

Illumina signs biobank deals to fuse genome data, EMRs

Illumina has signed deals to genotype the sample collections at four biobanks. Each of the projects is aiming to build a repository of linked genotypic and phenotypic data, with the sequencing results generated by Illumina being paired to electronic medical records (EMRs) possessed by the owners of the biobanks.

MORE NEWS

From Our Sister Sites

FierceBiotech

Mary Szela, the new CEO at Cambridge, MA-based Aegerion, has reached for the budget ax to help compensate for the rising tide of competition that has challenged its cholesterol drug Juxtapid. The company announced today that it is chopping about 25% of its staff--roughly 80 workers--as it whittles its roster of employees down to 230.

FierceCRO

Contract drugmaker Recipharm is promising to spend $45 million (€40 million) over the next three years to improve drug traceability in an effort to comply with new regulations and combat the rise of fake medicines.